Redeye updates its view following Ferroamp’s strong Q4 report, which showed 95% sales growth and mat...
Redeye retains its positive view of Carasent following the Q4 report.
* We expect 50% organic growth in Q4e * Q4 mix is likely to be somewhat soft * FVR of SEK 30-45 reit...
* Strong US performance more than offsets German weakness * EBIT up by 5-9% for '26e-'27e, driven by...
* Sales up 3% y-o-y, held back by soft volumes and tough comps * We keep sales flat, and slightly ra...
* Offering a business opportunity to system operators * Identifying the potential in closed-loop sys...
Redeye expects Smart Eye’s Q4 report, due 17 February, to show 13% y/y net sales growth and to reach...
Advenicas vd Marie Bengtsson gästar Västra Hamnens studio och diskuterar bolagets Q4-rapport, händel...
Redeye concludes that Litium delivered a strong Q4, with ARR growth of 18% including Geins and organ...
* We cut 2026e EBIT 4%, 2027e unchanged * Potential for large order signings near-term * Reiterate f...
* A soft end to '25 on earnings * We cut '26e-'27e adj.
Redeye comments on Active Biotech's fourth quarter report.
Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report.
Vd Joakim Samuelsson diskuterar bokslutsrapporten, händelser under året, affärsmodellen, samt möjlig...
Marimekko's Q4 came in slightly below our estimates, with profitability disappointing, particularly ...
Tekova’s Q4 was strong but EBIT guidance for 2026 was wide.
Q4 results came in below expectations but showed slight y/y improvement.
Raute’s margins were again higher than we estimated, however orders were still soft relative to our ...
Redeye sees Safeture’s Q4 2025 report to be another step in the right direction, with positive ARR g...
Redeye provides its initial take on Relais’ Q4 2025 report, which featured an adjusted EBITA that al...
